Valensa Granted Licenses for BiovaFlex(TM) Water-Soluble Egg Shell Membrane Ingredient

Friday, February 19, 2010 Drug News
Email Print This Page Comment
Font : A-A+

Agreement Will Allow Valensa to Introduce State-of-the-Art Joint Health Formulations Featuring High Efficacy and Smaller Pill Sizes

For further information, contact:

Dr. Rudi Moerck, President & CEO

Voice: 352-357-2004 ext. 701

Fax: 352-483-2095

http://www.valensa.com



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement
Advertisement

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook